The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.
|Number of pages||7|
|Journal||Australian and New Zealand Journal of Obstetrics and Gynaecology|
|Early online date||22 May 2019|
|Publication status||Published - Aug 2019|
- hypertensive disorders in pregnancy